Annie Joseph (@anniejoseph)

Sex & gender in Infection... its complicated!!!

Such a pleasure to host these guests alongside @erinmccreary.bsky.social

#IDSky #UTIsky #clinmicro
@escmid.bsky.social

09.03.2026 07:40 👍 8 🔁 3 💬 0 📌 0

Celebrating World Book Day tonight with the wonderful clever women in our book club, 'Reading Between The Wines'.

My 2025 New Years' resolution of starting a book club is turning out so much better than I could have anticipated 🍷 📚 🤓 💖

06.03.2026 19:18 👍 3 🔁 0 💬 0 📌 0

I love my boys' Headteacher calling a World Book Day amnesty, they get an author to come read to them instead!!

05.03.2026 20:08 👍 0 🔁 0 💬 1 📌 0

Completely. I'm hoping DURATIONS will help with lots of questions!

05.03.2026 15:06 👍 1 🔁 0 💬 0 📌 0

Looking forward to all the submissions! And she's right, the UTI clinic is the place to be 💪🏽

03.03.2026 07:35 👍 1 🔁 0 💬 0 📌 0

Kind of 🤣

02.03.2026 20:30 👍 2 🔁 0 💬 0 📌 0

When the drug is licensed for that indication (but that license may be very old and data has not been updated/revisited)?

Its a gap in antimicrobial governance & practice for many common abx that are used in UK. Licensed doses and indications are often not in line with current practice/evidence.

02.03.2026 19:21 👍 2 🔁 0 💬 1 📌 0

The fact that NICE recommended it without these key pieces of supporting data is fairly concerning.

However, I admit to recommending it frequently as 1g QID for fully sens E.coli pyelo in pts who settle quickly...

02.03.2026 19:09 👍 2 🔁 0 💬 2 📌 0

Of titans and taxonomy: The naming of Cronobacter sakazakii

📣 Person behind the name

Riichi Sakazaki identified Enterobacter sakazakii, a cause of neonatal sepsis

The genus was renamed Cronobacter after Cronos, the Greek god who devoured his children to prevent their supplanting him

#IDSky #clinmicro Saied Ali

https://ow.ly/ifFo50YlJkp

26.02.2026 08:40 👍 4 🔁 2 💬 0 📌 1

Register now for our first webinar of 2026!!! 🎉🥳🎊

#UTISky #IDSky #ESGUTI #ESCMID

17.02.2026 16:07 👍 5 🔁 3 💬 0 📌 1

Weighted-incidence syndromic combination antibiogram (WISCA) to guide antibiotic regimens for empiric treatment of prosthetic joint infections: A retrospective cohort study Prosthetic joint infections (PJIs) are now routinely treated with oral antibiotics, but selecting empiric regimens is challenging, including for treatment of culture-negative PJIs. Although antibiogra...

📣 What is a #WISCA?

It's something you should probably use for culture-negative prosthetic joint infections. Local antibiograms alone can be misleading.

This WISCA showed that doxycycline + a fluoroquinolone offer best coverage for #PJI

#IDSky #clinmicro #ortho
www.cmi-comms.org/article/S295...

12.02.2026 10:10 👍 12 🔁 7 💬 0 📌 5

📘Infection Prevention in Practice (IPIP) is seeking a new Editor to join the team📘

If you are passionate about IPC and wish to contribute to the international academic community, we encourage you to apply.

▶️Read more and apply now: https://ow.ly/GRlJ50Y08mL

10.02.2026 10:00 👍 0 🔁 2 💬 0 📌 0

📣 New #Communicable drops Mon 26 Jan! In our last episode, we brought you some favorite #clinmicro papers of 2025. We continue this thread in our next episode with top ID papers of 2025, picked by our editors, Josh Davis & Emily McDonald and guest, Steven Tong. ⭐ Tune in Monday🎙️

#IDSky

22.01.2026 10:45 👍 8 🔁 5 💬 0 📌 1

The beating heart of a broken machine

📣 A peer reviewer used #AI to create a fake review with 6 self-citation prompts. But is s/he the only perpetrator in our system? In the year's first editorial, Angela Huttner explores the depths of the academic-industrial complex.

#IDSky #clinmicro #peerreview

https://ow.ly/juoW50Y05t6

20.01.2026 14:23 👍 14 🔁 10 💬 2 📌 1

Microbiology royalty: Elizabeth O. King and the legacy of Elizabethkingia meningoseptica The genus Elizabethkingia comprises Gram-negative, nonmotile, nonspore-forming aerobic rods in the family Weeksellaceae. These nonglucose-fermenting organisms were long included within Flavobacterium ...

📣 Who is behind #Kingella kingae, #Elizabethkingia
meningoseptica, and several other bacteria? Anne-Marie Dolan et al describe the legacy of Elizabeth O. King, #CDC microbiologist & World War II army officer, for our #Personbehindthename series.

#IDSky #clinmicro

www.cmi-comms.org/article/S295...

12.01.2026 12:40 👍 103 🔁 30 💬 1 📌 0

I love the graphics in this paper too, the data visualisation was very high quality!! 👌

12.01.2026 13:15 👍 3 🔁 0 💬 1 📌 0

🎙️ Just published Communicable E44: Top clinical microbiology papers in 2025

Hosted by Annie Joseph & Josh Nosanchuk w/ invited guests Robin Patel & Fidelma Fitzpatrick

Listen on #Communicable: https://share.transistor.fm/s/6e5c26ae

#IDSky #clinmicro

11.01.2026 23:00 👍 10 🔁 5 💬 0 📌 3

📣 New #Communicable drops Mon 12 Jan! We kick off the new year with Annie Joseph & Josh Nosanchuk hosting Robin Patel (Mayo Clinic) & Fidelma Fitzpatrick (RCSI) to discuss their top #clinmicro papers of 2025 ⭐ Tune in Monday🎙️

#IDSky

08.01.2026 10:55 👍 13 🔁 4 💬 0 📌 0

An integrated surveillance study of SARS-CoV-2, influenza virus, and respiratory syncytial virus infections We aimed to describe recent epidemiological trends of SARS-CoV-2, influenza virus (A/B), and respiratory syncytial virus (RSV) in the canton of Geneva, Switzerland, using data from the Sentinella netw...

📣 #Wastewater surveillance is a powerful tool. In this integrated molecular epidemiologic study of >1000 patients with #influenza, #RSV, or #Covid, it correlates year after year with number of inpatient + ambulatory cases.

#IDSky #clinmicro #ViroSky #EpiSky #OA
www.cmi-comms.org/article/S295...

06.01.2026 08:14 👍 16 🔁 3 💬 0 📌 0

🎖️📄Top infectious disease journal articles from 2025 is out! May be good for a quick review to see if you missed anything or if you need to pick a journal club article. #pharmacist #infectiousdiseases #pharmacyschool #FYP #IDstewardship @absteward.bsky.social

www.idstewardship.com/year-in-revi...

29.12.2025 17:25 👍 19 🔁 8 💬 3 📌 1

Communicable E43: Katie's picks Podcast Episode · Communicable · 28/12/2025 · 47m

Great whistle-stop tour of @cmicomms.bsky.social’s podcast episodes.

This is one of my favourite podcasts

podcasts.apple.com/gb/podcast/c...

29.12.2025 17:28 👍 5 🔁 1 💬 1 📌 0

🎙️ Just published #Communicable E43: Katie's picks of 2025

Hosted by Angela Huttner & Annie Joseph w/ invited 'guest' Katie Hostettler, managing editor at CMI Communications & Communicable producer

Listen on #Communicable: https://share.transistor.fm/s/0da740f3

28.12.2025 23:00 👍 6 🔁 3 💬 1 📌 1

Alone at Christmas? #joinin is always good.

23.12.2025 14:46 👍 101 🔁 71 💬 0 📌 1

📣 New #Communicable drops Mon 29 Dec!
In this year-end special, Angela Huttner & Annie Joseph invite managing editor & Communicable producer Katie Hostettler to discuss her favorite episodes. Also, all editors share some of their highlights of the year.❄️🧣

#IDSky #clinmicro

23.12.2025 10:15 👍 10 🔁 3 💬 1 📌 0

Redirecting

🩸 Sepsis: Can "Time to Positivity" (TTP) be a free, immediate diagnostic tool?

Our study (in vitro + 151k vials) suggests TTP predicts species before identification.

Thread on clinical rules ⤵️ doi.org/10.1016/j.di... #ClinMicro #IDSky #Sepsis #MedSky

20.12.2025 08:31 👍 4 🔁 2 💬 1 📌 0

🆕⚡🧬 How Long Is Long Enough? — CBP Antibiotic Durations Still Built on Sand | CMI Communications, 2025
Current 4–6 wk FQ/TMP-SMX CBP regimens = thin evidence. Data mostly 4 wks (82%), shorter/longer durations poorly supported. RCTs needed #idsky #EMIMCC
www.sciencedirect.com:5037/science/arti...

07.12.2025 17:33 👍 5 🔁 2 💬 0 📌 1

Listening, learning and leading: empowering the next generation through podcast reviewing Launched in spring 2024, the podcast Communicable, hosted by the editors of CMI Communications, has quickly become a trusted forum for exploring emerging and sometimes controversial issues in infectio...

📣Extra proud of this one:

ESCMID's Trainee Assoc @taescmid.bsky.social reflects on its critical role in peer-reviewing #Communicable podcast episodes:

Our model "sets a precedent for inclusive academic publishing" 😀🎙️
#IDSky #clinmicro #MedEd #MedSky #peerreview

www.cmi-comms.org/article/S295...

02.12.2025 16:14 👍 3 🔁 3 💬 0 📌 0

Twitter remains a haven of harassment To the Editor,I read with interest the article by Stone and Schwartz “Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter),” October 2025 [1]. For disclosure, I was an early ScienceTwitter adopter, having established my account in 2009. Before Elon Musk purchased the site in October 2022, I had approximately 132 000 followers and received my “blue check” verification in 2016. I coauthored a 2020 publication touting the “viral power of Twitter for infectious disease” [2]. I coedited a book on the West African Ebola epidemic with colleagues I met via Twitter and credit the site with other collaborations and talk invitations over the years. All of this is to say that I have seen the highs and lows of the site in my 16 years’ worth of observations.One thing I find missing in the Stone and Schwartz [1] analysis is a discussion of the social cost of harassment and threats on Twitter/X, particularly for women. To be sure, Twitter was never a bucolic haven of civility. A preMusk, 2018 report by Amnesty International detailed a “shocking scale of online abuse against women” on the site [3], which increased further during the height of the COVID-19 pandemic [4]. I have personally received harassment from my years on Twitter, ranging from threats to my livelihood, to sexual assault, to wishes of death, and other graphic physical abuse. Most women scientists I know have received similar threats to one extent or another, and it is generally worse for women colleagues of colour [3]. Outspoken women with deep scientific expertise are intensely threatening to patriarchal norms and the extremists who have made their home on Musk’s Twitter.Stone notes that “Staying the course needs a thick skin—but ultimately science and reason can still shine even in the most hostile environment.” I would have once agreed with that statement, but I am no longer convinced. As noted in the original article, part of Musk’s changes upon site purchase were to eliminate much of the existing trust and safety team; to loosen moderation and allow for, or even reward via algorithmic boosting, misinformation on the platform; and to bring back users who had been banned under the prior owners, including those who had promoted vitriolic campaigns against scientists. The already-toxic platform showed an increase in hate speech as an unsurprising outcome [5]. Although the reporting feature was always unreliable, now the option to report an individual user or tweet has been removed altogether, an acknowledgement that there is no behaviour too odious to result in removal from the platform.I have been a science communicator on various sites since 2002, from internet fora to science blogs to Twitter and other social media sites. The depth of my skin is not the issue. Since the Musk takeover, 20 000 of my followers left the site. Because I will not participate in Musk’s new version of pay-to-play verification to boost the position of my tweets in the algorithm, my engagement on the site cratered. Although my profile still exists, I ended active participation in the summer of 2024. I no longer recommend the site to trainees and junior colleagues, as the risk of personal hazard is too great for the minimal engagement in return. Although neither is without fault, I currently find more engagement and productive discussion at Bluesky and Facebook.CRediT authorship contribution statementTara C. Smith: Conceptualization, Writing – original draft.Declaration of competing interestTara Smith has no COI to disclose. No funding was provided for this manuscript. No AI was used in its writing.

Author with 132K followers lost 20K post-Musk takeover 😞. Harassment, esp. vs women, rose 📈. Reporting removed, engagement crashed. Recommends Bluesky & Facebook over X.

#idsky

02.12.2025 14:30 👍 2 🔁 1 💬 0 📌 0

Diagnostic stewardship improves pt care, saves money, & makes doctors' lives easier... what's not to love?

Recording this ep gave me loads of ideas to put into practice...

01.12.2025 08:59 👍 4 🔁 2 💬 0 📌 0

<em>Communicable</em> episode 26: SNAP out of it—rethinking antistaphylococcal penicillins for <em>Staphylococcus aureus</em> bacteraemia, the SNAP trial PSSA/MSSA results In this first-ever collaboration between Communicable and Breakpoints, the podcast of the US Society of Infectious Diseases Pharmacists, hosts Angela Huttner (Geneva, Switzerland) and Erin McCreary (Pittsburgh, USA) join trial investigators Josh Davis (Newcastle, Australia) and Steven Tong (Melbourne, Australia) to unpack the first results coming from the SNAP adaptive platform trial, which were recently presented at ESCMID Global in Vienna. Learn whether penicillin and cefazolin are non-inferior to—and maybe even safer than—flucloxacillin for penicillin-susceptible and methicillin-susceptible Staphylococcus aureus, respectively.This episode was edited by Julie Anne Justo, transcribed by Katie Lambert and Sarah Groome, and peer-reviewed by Megan Klatt and Lacy Worden. Communicable and Breakpoints released this episode on 5 May 2025.Declaration of competing interestS.Y.C.T. has served on an advisory board for AstraZeneca for a staphylococcal monoclonal antibody programme and receives royalties from UpToDate for editing S. aureus–related content. E.K.M. has previously served on scientific advisory boards for the following pharmaceutical companies: Abbvie, Basilea, Melinta, GSK, and serves on the DSMC for the SNAP trial. Other authors declare no financial interests/personal relationships that may be considered as potential competing interests. Note on conflict of interest for SNAP Data Safety Monitoring Committee (DSMC) members:Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationships that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner.Related podcast episodeCommunicable Episode 26: SNAP out of it - the SNAP trial PSSA/MSSA results https://share.transistor.fm/s/2a3c3bb4Further reading[1]Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61. DOI:https://doi.org/10.1128/CMR.00134-14.[2]SNAP Adaptive trial platform/results of the PSSA & MSSA domains:• https://www.snaptrial.com.au/ESCMID Global April 2025 presentation:• www.online.escmid.org *• https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/[3]CloCeBa trial results (ESCMID Global April 2025 presentation):• www.online.escmid.org *• https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/[4]CAMERA 2 trial; Tong SY, Lye DC, Yahav D, et al. Without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–37. DOI:https://doi.org/10.1001/jama.2020.0103.[5]POET trial; Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–24. DOI:https://doi.org/10.1056/NEJMoa1808312.[6]POET trial follow-up: Pries-Heje MM, Wiingaard C, Ihlemann N. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. N Engl J Med. 2022;386:601–02. DOI:https://doi.org/10.1056/NEJMc2114046.*Note on access to online video of ESCMID Global presentations:•In the six months following the congress:• Non-ESCMID members have access if they registered for ESCMID Global• Members have access only if they registered for ESCMID Global•Six months after the congress:• Non-members do not have access, whatever their ESCMID Global registration status• All members have access, whatever their ESCMID Global registration status

Podcast reveals SNAP trial: penicillin & cefazolin non-inferior & possibly safer than flucloxacillin for PSSA/MSSA. Episode aired May 5, 2025. 🎧🦠 #InfectDis

#idsky

30.11.2025 13:00 👍 4 🔁 1 💬 0 📌 0

Annie Joseph

Latest posts by Annie Joseph @anniejoseph